Cargando…

Detection of mutant antigen-specific T cell receptors against multiple myeloma for T cell engineering

Multiple myeloma (MM) remains an incurable hematological neoplasm. Neoantigen-specific T cell receptor (TCR)-engineered T (TCR-T) cell therapy is a potential alternative treatment. Particularly, TCRs derived from a third-party donor may cover broad ranges of neoantigens, whereas TCRs in patients suf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okada, Masahiro, Shimizu, Kanako, Nakazato, Hiroshi, Yamasaki, Satoru, Fujii, Shin-ichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10285226/ https://www.ncbi.nlm.nih.gov/pubmed/37359417 http://dx.doi.org/10.1016/j.omtm.2023.05.014

Ejemplares similares

Vaccine Designs Utilizing Invariant NKT-Licensed Antigen-Presenting Cells Provide NKT or T Cell Help for B Cell Responses
por: Fujii, Shin-ichiro, et al.
Publicado: (2018)

Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity
por: Fujii, Shin-ichiro, et al.
Publicado: (2022)

Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ
por: Fujii, Shin‐ichiro, et al.
Publicado: (2022)

Optimal therapeutic strategy using antigen‐containing liposomes selectively delivered to antigen‐presenting cells
por: Iyoda, Tomonori, et al.
Publicado: (2019)

NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies
por: Shimizu, Kanako, et al.
Publicado: (2020)

Zeb2 regulates differentiation of long-lived effector of invariant natural killer T cells
por: Iyoda, Tomonori, et al.
Publicado: (2023)

In vivo dendritic cell targeting cellular vaccine induces CD4(+) Tfh cell-dependent antibody against influenza virus
por: Yamasaki, Satoru, et al.
Publicado: (2016)

Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy
por: Okada, Masahiro, et al.
Publicado: (2022)

Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer
por: Iyoda, Tomonori, et al.
Publicado: (2023)

Eomes transcription factor is required for the development and differentiation of invariant NKT cells
por: Shimizu, Kanako, et al.
Publicado: (2019)

A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma
por: Dhodapkar, Madhav V., et al.
Publicado: (2003)

Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2
por: Shimizu, Kanako, et al.
Publicado: (2021)

Transfer of mRNA Encoding Invariant NKT Cell Receptors Imparts Glycolipid Specific Responses to T Cells and γδT Cells
por: Shimizu, Kanako, et al.
Publicado: (2015)

Exploiting Antitumor Immunotherapeutic Novel Strategies by Deciphering the Cross Talk between Invariant NKT Cells and Dendritic Cells
por: Fujii, Shin-ichiro, et al.
Publicado: (2017)

Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response
por: Fujii, Shin-ichiro, et al.
Publicado: (2013)

RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
por: Harrer, Dennis C., et al.
Publicado: (2017)

Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma
por: Cichocki, Frank, et al.
Publicado: (2022)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma
por: Perez-Amill, Lorena, et al.
Publicado: (2020)

Chimeric antigen receptor T cell therapy for multiple myeloma
por: Hasegawa, Kana, et al.
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
por: Hosen, Naoki
Publicado: (2019)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells
por: Shimizu, Kanako, et al.
Publicado: (2007)

A single immunization with cellular vaccine confers dual protection against SARS‐CoV‐2 and cancer
por: Shimizu, Kanako, et al.
Publicado: (2022)

Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein
por: Fujii, Shin-ichiro, et al.
Publicado: (2003)

Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma
por: Tang, Fang, et al.
Publicado: (2020)

Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8(+) T cells against tumor
por: Shimizu, Kanako, et al.
Publicado: (2023)

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
por: Ma, Tiantian, et al.
Publicado: (2019)

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)

Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma
por: Padda, Jaskamal, et al.
Publicado: (2021)

Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma
por: Fang, Yi, et al.
Publicado: (2021)

Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2/Mcl-1 pathway
por: SADAHIRA, KEN, et al.
Publicado: (2014)

PD-L1 Expression Affects Neoantigen Presentation
por: Okada, Masahiro, et al.
Publicado: (2020)

Characteristics of a Novel Target Antigen against Myeloma Cells for Immunotherapy
por: Matsushita, Maiko, et al.
Publicado: (2020)

Identification and Targeting of Mutant Neoantigens in Multiple Myeloma Treatment
por: Brancati, Valentina Urzì, et al.
Publicado: (2023)

CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma
por: Chu, Jianhong, et al.
Publicado: (2013)

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial
por: Schmitt, Michael, et al.
Publicado: (2016)

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
por: Cronk, Robert J., et al.
Publicado: (2020)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
por: Mishra, Abhinava K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_je2ed3elc4cg1a4t94p8sugr7h